Tisocalcitate
Alternative Names: Psoriasis therapy - Bayer Schering PharmaLatest Information Update: 22 Mar 2010
At a glance
- Originator Bayer Schering Pharma
- Class Antipsoriatics; Vitamin D analogues
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
- 03 Mar 2004 Data presented at the 62nd Annual Meeting of the American Academy of Dermatology (AAD-2004) have been added to the adverse events and pharmacokinetics sections ,
- 12 May 2003 Phase-II clinical trials in Psoriasis in Europe (Topical)